Analytical Data
-
基因名
MOGAT2
- Application
-
别名
MOGAT2；DC5；DGAT2L5；2-acylglycerol O-acyltransferase 2
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q3SYC2
-
表达区间
1-334aa
-
氨基酸序列
MVEFAPLFMPWERRLQTLAVLQFVFSFLALAEICTVGFIALLFTRFWLLTVLYAAWWYLDRDKPRQGGRHIQAIRCWTIWKYMKDYFPISLVKTAELDPSRNYIAGFHPHGVLAVGAFANLCTESTGFSSIFPGIRPHLMMLTLWFRAPFFRDYIMSAGLVTSEKESAAHILNRKGGGNLLGIIVGGAQEALDARPGSFTLLLRNRKGFVRLALTHGAPLVPIFSFGENDLFDQIPNSSGSWLRYIQNRLQKIMGISLPLFHGRGVFQYSFGLIPYRRPITTVVGKPIEVQKTLHPSEEEVNQLHQRYIKELCNLFEAHKLKFNIPADQHLEFC
-
分子量
38.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MOGAT2, or monoacylglycerol O-acyltransferase 2, is an enzyme that plays a crucial role in lipid metabolism, particularly in the synthesis of triacylglycerols (TAGs) from monoacylglycerols (MAGs) and acyl-CoA substrates. Understanding MOGAT2's function and regulation is vital due to its implications in metabolic disorders such as obesity, diabetes, and cardiovascular diseases. The enzyme is involved in the endocannabinoid system, contributing to the modulation of various physiological processes including appetite regulation and energy homeostasis. Research has revealed that dysregulation of MOGAT2 may lead to altered lipid profiles and increased risk of metabolic diseases. Consequently, MOGAT2 has emerged as a potential therapeutic target for drug development aimed at managing obesity and its associated conditions. Studies involving the recombinant expression of MOGAT2 proteins facilitate the investigation of its biochemical properties, enzyme kinetics, and interaction with other metabolic pathways. Furthermore, understanding the structural characteristics of MOGAT2 through techniques such as X-ray crystallography and cryo-electron microscopy could offer insights into its mechanism of action, guiding the design of specific inhibitors or modulators. Overall, ongoing research on MOGAT2 aims to elucidate its role in lipid metabolism and its potential as a target for therapeutic interventions in metabolic diseases.
